Core Bugs and Drugs
This course is already included in the Core Antimicrobial Stewardship Curriculum. You do not need to purchase access to this course, if you already have access to the Core Antimicrobial Stewardship Curriculum.
Included as the first section of IDSA's Core Antimicrobial Stewardship Curriculum, the new Bugs and Drugs primer is being offered independently for learners. Ideal for medical students, residents, fellows, and early career professionals, this primer covers key microbiology and pharmacology concepts, as well as case-based exercises on management of Gram positive and Gram negative organisms; to provide a foundation for stewardship principles and practice along with many other high yield concepts.
Content in this section is available through (7) eLearning modules. The 7 modules include:
Module 1: Foundations of Microbiology - Susceptibility Testing and Rapid Diagnostics
Module 2: Foundation of Pharmacology
Module 3: Foundations - Case One
Module 4: Foundations - Case Two
Module 5: Foundations - Case Three
Module 6: Foundations - Case Four
Module 7: Foundations - Case Five
Target Audience
Ideal for medical students, residents, fellows and others who desire to learn more about key microbiology and pharmacology concepts. This primer can be used collaboratively in a classroom setting, or completed independently. Please reach out to academy@idsociety.org for more information about how to best utilize this curriculum for your particular needs.
Learning Objectives
Bugs (Microbiology) Learning Objectives:
- Describe methods, use and limitations of culture and non-culture based rapid diagnostic tests most relevant to the practice of antimicrobial stewardship
- Describe commonly utilized methods of antimicrobial susceptibility testing in the clinical microbiology lab and explain benefits and limitations of each method
- Describe principles of MIC interpretation and apply practical CLSI data effectively when considering a case
- Discuss rapid diagnostic and resistance/susceptibility testing principles most important to the major bacterial pathogens (S.aureus, Enterobacterales, Pseudomonas, Enterococcus) relevant to stewardship
Drugs (Pharmacology) Learning Objectives:
- Describe general concepts and principles of the pharmacokinetics/pharmacodynamics (PK/PD) of antimicrobials
- Identify PK/PD indices of specific antimicrobials most associated with bacterial eradication.
- Characterize how drug exposure impacts antimicrobial efficacy, toxicity and resistance in order to design appropriate antimicrobial regimens
- Identify clinical circumstances favoring the performance of antimicrobial Therapeutic Drug Monitoring (TDM) (e.g. available drug assay, unpredictable drug dose-exposure relationship, clear relationship between drug exposure and efficacy and/or toxicity)
- Apply PK/PD data, target indices, and therapeutic drug monitoring to the design of appropriate antimicrobial regimens for patients with altered pharmacokinetics and/or in special populations
AS Curriculum Workgroup COI Summary Reviewed April 2017 by Rachel Simmons, MD No conflicts found.
All relevant financial relationships have been mitigated.
Name | Individual's role in activity | Name of commercial interest | Nature of Relationship |
---|---|---|---|
Advani, Sonali | Workgroup Member | None | |
Armstrong, Wendy | Workgroup Member | None | |
Barsoumian, Alice | Workgroup Member | None | |
Beeler, Cole | Workgroup Member | None | |
Bennani, Kenza | Staff | None | |
Blair, Barbra | Workgroup Member | None | |
Brennan - Krohn, Thea | Workgroup Member | None | |
Bryson - Cahn, Chloe | Workgroup Member | None | |
Cherabuddi, Kartik | Workgroup Member | None | |
Fong, Gary | Workgroup Member | Critical Innovations, LLC | Advisory/Consultant Role |
Gaston, David | Workgroup Member | None | |
Hamilton, Keith | Workgroup Member | None | |
Holubar, Marisa | Workgroup Member | None | |
Huang, Misha | Workgroup Member | None | |
Ince, Dilek | Workgroup Member | Gilead Science’s Clinical Studies for remdesivir | Principal Investigator |
Accelerate Diagnostics | Research Grants/Contracts | ||
Leidos | Research Grants/Contracts | ||
Justo, Julie Ann | Workgroup Member | bioMerieux | Other remuneration - Speaker's Bureau |
Merck | Advisory/Consultant Role | ||
Vaxart | Stocks/Bonds | ||
Kang, Amy | Workgroup Member | None | |
Larnard, Jeff | Workgroup Member | None | |
Lee, Matthew | Workgroup Member | None | |
Logan, Ashleigh | Staff | None | |
Luther, Vera | Workgroup Member | None | |
MacDougal, Conan | Workgroup Member | None | |
Melia, Michael | Workgroup Member | Merck | Organizational Benefit |
Allergan | Organizational Benefit | ||
Pfizer; Melinta | Organizational Benefit | ||
Miller, Matt | Workgroup Member | Abbvie | Honoraria |
La Jolla | Honoraria | ||
Merck | Research Grant/Contract | ||
Moenster, Ryan | Workgroup Member | Shionogi | Advisory/Consultant Role, Honoraria |
Abbvie/Allergan | Advisory/Consultant Role, Honoraria | ||
Melinta Therapeutics | Advisory/Consultant Role, Honoraria | ||
Merck | Advisory/Consultant Role, Honoraria | ||
Nori, Priya | Workgroup Member | Merck | Co-infections in COVID-19 patients |
Paras, Molly | Workgroup Member | None | |
Patel, Payal | Workgroup Member | None | |
Rodvold, Keith | Workgroup Member | BLC USA LP | Advisory/Consultant Role, Honoraria |
VenatoRx | Advisory/Consultant Role, Honoraria | ||
Medicine Company/Qpex Biopharma | Advisory/Consultant Role, Honoraria | ||
Vemco Med Ed. (Merck CME/CPE programs) | Advisory/Consultant Role, Honoraria | ||
Debipharm | Advisory/Consultant Role, Honoraria | ||
Shionogi | Advisory/Consultant Role, Honoraria | ||
Unrestricted education grant for CME/CPE Program | |||
Utility Therapeutics | Advisory/Consultant Role, Honoraria | ||
Janssen | Data Safety Monitoring Board (DSMB) | ||
Clinartis LLC (projects associated with Spero Therapeutics and Sinovent) | Advisory/Consultant Role, Honoraria | ||
USCAST : US Ctte on Antimicrobial Susceptibility Testing | Voting Committee Member | ||
Schooneveld, Trevor | Workgroup Member | Rebiotix, Merk | Research Grant |
Thermo - Fischer | Speaking | ||
Schwartz, Brian | Workgroup Member | None | |
Spicer, Jennifer | Workgroup Member | None | |
Stack, Conor | Workgroup Member | None | |
Stead, Wendy | Workgroup Member | None | |
Stohs, Erica | Workgroup Member | Reviral Ltd | Research Grant |
Wiley, Zanthia | Workgroup Member | None | |
Willis, Zachary | Workgroup Member | None | |
Shnekendorf, Rachel | Staff | None | |
Vaezi, Liza | Workgroup Member | None | |
Rachel Simmons | Reviewer | None |